Anshul Mangal (President of Project Farma and Precision ADVANCE) and Phil Cyr (SVP, Customer Solutions at Precision Value & Health) sat down with Samantha Black (Editor in Chief at ScienceBoard) to discuss how Precision ADVANCE is driving innovation in the advanced therapy sector by improving patient access through interconnected services across the drug development spectrum.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
